Vision Institute (Institut de la Vision) | |
Founder: | Jose-Alain Sahel |
Established: | 2008 |
Focus: | Eye diseases |
President: | Jose-Alain Sahel |
City: | Paris |
Country: | France |
Address: | 17 rue Moreau 75012 Paris |
Website: | http://www.institut-vision.org/ |
The Vision Institute (French: Institut de la Vision) is a research center in the Quinze-Vingts National Eye Hospital in Paris, France. It is one of several such centers (Inserm / UPMC / CNRS) in Europe on eye diseases.[1]
The Institute's goal is to discover, develop and test treatments and technological innovations in the area ophthalmology and to improve the autonomy and the quality of life of patients.[2]
Vision Institute employs more than 250 scientists (Inserm - UPMC - CNRS) specialized in vision disorders.
There are 4 research departments:[3]
The Ophthalmological Clinical Investigation Centre of the Quinze-Vingts National Eye Hospital opened in 2004.
The Clinical Investigation Centre covers all eye diseases but is specialised in exploration of retinal pathologies (macular degeneration, hereditary retinal degenerations, diabetic retinopathies, retinal vascular pathologies) and technological innovations.
The Vision Institute runs a StreetLab Platform Project. The StreetLab platform enables researchers to design and develop innovative technology solutions for the visually impaired while being able to evaluate the therapeutic benefit of this research directly with the people involved.[2]
The Foundation Voir et Entendre was created in May 2007 by Prof. Christine Petit (Institut Pasteur, Collège de France) and Prof. José-Alain Sahel.
The Foundation's objective is to coordinate and to finance research programs on ocular and auditory diseases. Its mission is to stimulate the collaboration between fundamental, clinical and industrial research, so as to accelerate therapeutic innovation for the benefit of the patients.[4]
Five major companies have settled in the Institute to develop research projects in the field of vision: Essilor, Sanofi Fovea, Thea, Horus Pharma and Iris Pharma.[5]